West Pharmaceutical raises 2026 guidance on 13.8% Q2 sales growth, 28.8% EPS jump

Filed July 23, 2026 · Period ending July 23, 2026 · ~1 min read

Key Changes

• high

  Q2 2026 net sales rose 13.8% to $872.3M (12.7% organic), driven by High Value Product Components (up 19.4%) and Delivery Devices (up 29.6%); adjusted EPS climbed 28.8% to $2.37 on 230bp margin expansion.

  Exhibit 99.1 view on EDGAR →
• high

  Full-year 2026 guidance raised: net sales now $3.345B–$3.380B (10.0%–11.0% organic growth, up from prior $3.295B–$3.350B) and adjusted EPS $8.85–$9.05 (up from $8.40–$8.75).

  Exhibit 99.1 view on EDGAR →
• high

  Proprietary Products segment (83% of revenue) grew 16.6% to $722.6M with operating margin expanding 320bp to 29.3%, fueled by biologics strength and GLP-1 elastomers (10% of total company sales).

  Exhibit 99.2 view on EDGAR →